Alginate Wound Dressing with Antiseptic Complexation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound dressings with antiseptic properties face challenges such as short-term stability, skin irritation, and reduced efficacy due to ion interactions, limiting their effectiveness in treating infected or contaminated wounds.
Innovation Solution
A wound dressing composed of alginate fibers impregnated with antiseptically active substances like biguanide derivatives, octenidine, or taurolidine, which maintain antimicrobial activity while allowing for moist wound treatment and promoting wound healing without adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiseptics are used in wound dressings, then antimicrobial activity is achieved, but stability and efficacy are reduced due to ion interactions
Solution Approach 1:
The patent uses alginate as an intermediary carrier that binds antiseptic substances (biguanide derivatives, octenidine, or taurolidine) through complexation with calcium ions. This intermediary mechanism protects the antiseptic from direct ion interactions that would reduce efficacy, while maintaining stable antimicrobial activity in the wound environment.
Solution Approach 2:
The invention creates a composite material system where alginate fibers are impregnated with antiseptic substances. This composite structure combines the gel-forming, absorbent properties of alginate with the antimicrobial activity of the antiseptic, achieving stable efficacy through the synergistic interaction of components.
2Reliability
If high concentrations of antiseptic are used, then antimicrobial efficacy is improved, but skin irritation and adverse effects increase
Solution Approach 1:
The patent optimizes the concentration parameter of antiseptic substances within specific ranges (biguanide derivatives: 0.1-10% w/w, octenidine: 0.01-1% w/w, taurolidine: 0.1-5% w/w). This parameter optimization achieves effective antimicrobial activity while minimizing skin irritation and adverse effects through controlled release from the alginate matrix.
Solution Approach 2:
The alginate matrix provides self-regulating controlled release of the antiseptic substance, maintaining effective concentrations at the wound site while preventing excessive local concentrations that would cause skin irritation. The material automatically modulates release based on wound exudate interaction.
3Quantity of substance
If alginate fibers are used for wound absorption, then exudate absorptivity is improved, but antiseptic stability is reduced due to gel formation
Solution Approach 1:
The patent merges two functions into a single integrated system: the alginate fibers provide both exudate absorption through gel formation and antiseptic delivery. The gel matrix that forms upon contact with exudate simultaneously absorbs wound fluid and stabilizes the antiseptic substance, preventing degradation while maintaining antimicrobial activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The alginate-based wound dressings demonstrate sustained antimicrobial activity against various pathogens, preventing infection spread and promoting wound healing, even at low antiseptic concentrations, thus overcoming limitations of existing antiseptics.
Implementation Method 1
Wound dressings or bandages of natural alginate fibers have good absorption capacity for wound exudate
Implementation Method 2
wound dressings of alginate fibers form a gel upon contact with wound exudate or blood
Implementation Method 3
bind bacteria, contained in the exudate, in the gel
Data Source
AI summary
An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also provided.